2852 Kelvin Avenue
566 articles with Masimo Corporation
Study Investigates the Ability of Masimo Noninvasive, Continuous Hemoglobin (SpHb®) to Provide Earlier Indication of Anemia and the Impact of Anemia on Patient Outcomes
Masimo announced that in a study published in Injury, researchers used Masimo SpHb® – noninvasive, continuous hemoglobin monitoring – to investigate possible delays in the detection of perioperative anemia assessed using invasive, intermittent laboratory hemoglobin values in elderly patients undergoing hip fracture surgery.
Masimo (NASDAQ: MASI) announced today three additional indices (delta cHb, delta HHb, and delta O2Hb) for O3® Regional Oximetry.
Masimo announced that its management is scheduled to present at the Morgan Stanley 17th Annual Global Healthcare Conference at the Grand Hyatt New York on Tuesday, September 10, 2019 at 3:30 p.m. Eastern Time.
Masimo Announces Pathway™, a Newborn Oxygenation Visualization Mode for the Root® Patient Monitoring and Connectivity Platform
Masimo (NASDAQ: MASI) today announced Pathway™, a feature for the Root® Patient Monitoring and Connectivity Platform. Pathway provides clinicians with a way to visualize a hospital’s recommended resuscitation protocol for a newborn’s oxygen saturation (SpO2) while continuously monitoring SpO2 and pulse rate (PR) during the first ten minutes after birth
Study Investigates the Utility of Masimo ORi™, Oxygen Reserve Index, to Reduce Hyperoxia in Critically Ill Patients
Masimo announced that in a randomized controlled study involving 150 ICU patients recently published as a letter in Intensive Care Medicine, researchers investigated whether monitoring with Masimo ORi™ could reduce the time critically ill patients spend with moderate hyperoxia, compared to monitoring with oxygen saturation alone.
Closed on a strategic investment with TNI medical AG, a privately held, commercial-stage medical device company headquartered in Würzburg, Germany.
Study Demonstrates Reduction in Mortality Using Masimo Noninvasive, Continuous Hemoglobin (SpHb®) and Pleth Variability Index (PVi®) Monitoring
Masimo announced that in a study published in the Journal of Clinical Monitoring and Computing, researchers investigated the effects of implementing a hospital-wide fluid and blood administration protocol using two Masimo measurements: noninvasive, continuous hemoglobin and pleth variability index.
Masimo Announces CE Marking of Neonatal Indication for Noninvasive, Continuous Hemoglobin Monitoring (SpHb®)
Masimo announced the CE marking of SpHb®, noninvasive and continuous hemoglobin monitoring, for neonatal and infant patients.
Masimo announced its financial results for the second quarter ended June 29, 2019.
Study Investigates the Ability of Continuous Noninvasive Hemoglobin Monitoring with Masimo SpHb® to Reflect Acute Hemodilution During Incremental Fluid Administration
Masimo announced that in a study recently published in Anesthesia & Analgesia, researchers evaluated the ability of noninvasive and continuous hemoglobin monitoring with Masimo SpHb® to detect the development of acute hemodilution after graded fluid administration, by comparing it to invasively measured laboratory hemoglobin, on patients undergoing major surgery.1
Conference call and webcast to begin at 1:30 p.m. PT (4:30 p.m. ET)
New Study Investigates the Utility of Masimo ORi™, Oxygen Reserve Index, As an Indicator to Avoid Hyperoxia During General Anesthesia
Masimo announced that in a study recently published in the Journal of Clinical Monitoring and Computing, researchers investigated the ability of Masimo ORi™ to serve as a noninvasive indicator of the arterial partial pressure of oxygen during general anesthesia, to help avoid hyperoxia.1 ORi is an index of oxygenation in the moderate hyperoxic region.
Masimo is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions.
With this expansion of the O3 platform, the benefits of monitoring with O3 are now available to patients of all ages, from neonates to adults.
New Study Evaluates Ability of Masimo SpHb® (Noninvasive Hemoglobin) to Estimate Timing for Invasive Measurement to Detect Anemia During Surgery
Masimo announced the results of a study published in BMC Anesthesiology in which clinicians at Peking Union Medical College in Beijing evaluated the ability of noninvasive and continuous hemoglobin monitoring with Masimo SpHb® to help clincians estimate when to conduct invasive hemoglobin measurement to detect possible anemia in patients undergoing spine or cytoreductive surgery.
Masimo Announces FDA Clearance of Radius PPG™, the First Tetherless SET® Pulse Oximetry Sensor Solution
Coupled with the proven benefits of Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, Radius PPG is suited for use anywhere patients can benefit from mobility.
A live audiocast of the presentations and accompanying slides will be available on the Investor Relations section at www.masimo.com.
Masimo announced that its management is scheduled to present at the UBS Global Healthcare Conference at the Grand Hyatt New York on Tuesday, May 21, 2019 at 2:00 p.m. Eastern Time.
Mindray to Offer Masimo SET® Pulse Oximetry in its Patient Monitoring Devices in Additional Countries Beyond the United States
Masimo announced its financial results for the first quarter ended March 30, 2019.